Oluyemi Okupe Sells 11,581 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $52.98, for a total transaction of $613,561.38. Following the completion of the sale, the chief financial officer now directly owns 39,153 shares in the company, valued at $2,074,325.94. This trade represents a 22.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, May 15th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $60.22, for a total transaction of $697,407.82.
• On Tuesday, April 15th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.50, for a total transaction of $330,058.50.
• On Wednesday, April 2nd, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.26, for a total transaction of $338,860.06.

Hims & Hers Health Price Performance

HIMS opened at $56.74 on Friday. The company has a fifty day moving average price of $39.85 and a 200-day moving average price of $36.07. The firm has a market capitalization of $12.70 billion, a P/E ratio of 128.96 and a beta of 1.84. Hims & Hers Health, Inc. has a one year low of $13.47 and a one year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.08. The firm had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business’s revenue for the quarter was up 110.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.05 EPS. On average, analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock valued at $489,817,000 after purchasing an additional 2,020,722 shares in the last quarter. Farallon Capital Management LLC grew its position in shares of Hims & Hers Health by 64,338.5% during the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after purchasing an additional 8,364,000 shares in the last quarter. Renaissance Technologies LLC grew its position in Hims & Hers Health by 29.0% in the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock worth $168,079,000 after acquiring an additional 1,562,302 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in Hims & Hers Health by 192.0% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock worth $152,436,000 after acquiring an additional 4,145,305 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Hims & Hers Health by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company’s stock worth $104,724,000 after acquiring an additional 40,447 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

HIMS has been the topic of a number of research reports. Morgan Stanley lowered their price target on shares of Hims & Hers Health from $60.00 to $40.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 29th. Leerink Partners lifted their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research note on Tuesday, February 25th. Truist Financial reduced their price objective on shares of Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating for the company in a research note on Thursday, April 10th. Bank of America lifted their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company an “underperform” rating in a research note on Tuesday, April 29th. Finally, Citigroup reiterated a “sell” rating and issued a $30.00 price objective (up from $25.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and an average price target of $37.67.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.